Repligen Corporation (NASDAQ:RGEN), a $9.36 billion market cap leader in bioprocessing technology, has been navigating a complex market landscape characterized by innovation, strategic acquisitions, ...
The company raised the midpoint of its revenue growth guidance, now expecting 14% to 15.5% organic non-COVID growth or 12% to 13.5% organic revenue growth for 2025, with the midpoint of both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback